Community pharmacy may be the most regulated small business in Australia. Your main revenue line is set by a five-year Commonwealth agreement, your dispensing economics shifted under 60-day prescriptions, your stock is your largest current asset and your easiest margin leak, and in NSW the law restricts who can own you at all. A pharmacist running a $4 million turnover business on 3–4% net margin has almost no room for accounting error — and a generalist accountant who does not know what an 8CPA fee line is will make those errors invisibly.

Trinity Accounting Practice has worked with Sydney healthcare and retail businesses since 2003, and pharmacy sits exactly at that intersection. This guide explains how PBS revenue actually works, what 60-day dispensing did to the model, the stock and margin disciplines that protect profit, NSW’s pharmacist-only ownership rules and the structures that fit inside them, and what the numbers look like when a pharmacy changes hands.

PBS revenue — a business where Canberra sets your prices

For most community pharmacies, 60–75% of revenue comes from dispensing, and the economics of every PBS script are built from regulated components under the Eighth Community Pharmacy Agreement (8CPA), which runs from 1 July 2024 to 30 June 2029:

The drug cost — what you pay the wholesaler, largely set by the PBS price.
Regulated fees — dispensing fee, Administration, Handling and Infrastructure (AHI) fee, and since the 8CPA, the Additional Community Supply Support (ACSS) payment introduced to support pharmacies through the 60-day changes.
The patient co-payment — from 1 January 2026 the general PBS co-payment dropped from $31.60 to $25 under the Cheaper Medicines legislation, while the concessional co-payment stays at $7.70. For scripts priced under the co-payment, you are effectively competing on price; above it, the Commonwealth pays the balance.

The accounting consequence: a pharmacy P&L cannot be read like a shop’s. Revenue mix between government-paid and patient-paid scripts, the timing of PBS claim payments, and fee indexation each July all need to be modelled, not discovered. A pharmacy accountant reconciles PBS payment statements against the dispense data — a control that catches claiming errors which otherwise quietly cost thousands a year.

60-day dispensing — the change still working through the model

From September 2023, many common medicines became eligible for 60-day prescriptions. For patients it halved co-payments; for pharmacies it restructured dispensing income — one dispensing event where there used to be two. The compensating mechanics under the 8CPA matter:

Industry analysis puts the average margin impact of a 60-day script at roughly $10 per dispensing versus the two-script alternative, though 60-day scripts remain a minority of most pharmacies’ volume.
The ACSS payment was introduced as compensation and doubled from $0.78 to $1.57 per eligible script from 1 July 2025 — meaning pharmacies with high 30-day volumes are partially insulated, while the net effect varies pharmacy by pharmacy.
The strategic response is not to mourn lost dispensing fees but to measure the gap and fill it: medication reviews, vaccinations, expanded scope services and front-of-shop performance all carry better margins than they did relative attention five years ago.

Every pharmacy owner should know, in dollars, what 60-day dispensing is doing to their gross profit each quarter. Most do not — because their accounts were never set up to show it.

Stock and gross margin — where pharmacy profit is actually won

Stock is typically a pharmacy’s largest current asset — often $250,000–$450,000 for a suburban Sydney pharmacy — and the place where margin quietly disappears. The disciplines we run with pharmacy-style retail clients:

Gross margin by department. Dispensary, over-the-counter medicines, vitamins, beauty, and gifts have completely different margin profiles. A blended “GP%” tells you nothing; a department-level report tells you where to put shelf space and buying effort.
Stock turn targets. Slow-moving front-of-shop stock ties up cash that the dispensary needs for wholesaler terms. Stock turning 8–12 times a year in the dispensary against 3–4 in retail is normal — below that, you are funding a museum.
Wholesaler terms and trading discounts. Settlement discounts for early payment are real margin — often 2.5% or more — but only capturable with disciplined cash flow. Missing them because the BAS and wages landed in the same week is a planning failure, not a finance cost.
Stocktake integrity. Shrinkage, expired stock write-offs and generic substitution economics need to be visible in the monthly accounts, not absorbed into an annual surprise.

Ownership rules in NSW — and the structures that fit inside them

NSW pharmacy ownership is restricted by law: under the Health Practitioner Regulation National Law (NSW), only registered pharmacists may hold a financial interest in a pharmacy business — as a sole trader, a partnership of pharmacists, or a pharmacists’ body corporate — and a person may hold a financial interest in no more than five pharmacies. The Pharmacy Council of NSW polices financial interests, and arrangements that give non-pharmacists effective ownership or control (disguised loans, profit-sharing leases, management agreements with equity characteristics) can put the pharmacy’s approval at risk.

Within those constraints, structuring still matters enormously:

Partnerships of pharmacists remain the classic vehicle for multi-owner pharmacies — with partnership agreements needing to deal with funding, exit, death and disability in an industry where the buyer pool is legally restricted.
Pharmacists’ body corporate structures can provide limited liability where all the ownership tests are met.
Service and asset arrangements — non-pharmacist family members cannot own the pharmacy, but properly structured arrangements around premises and genuine non-pharmacy services may still be possible. The line between legitimate structuring and a prohibited financial interest is exactly where specialist advice earns its keep, and the Pharmacy Council’s view should be respected as conservative.
Income tax overlay. The PSI rules, partnership taxation, and the small business CGT concessions all interact with the ownership rules. A structure that satisfies the Pharmacy Council but wrecks the CGT concession eligibility on exit is half a job.

Wages, the award and payroll tax

Pharmacy wages run 10–14% of turnover and carry their own traps: the Pharmacy Industry Award’s classification levels (pharmacist, experienced pharmacist, pharmacist-in-charge, pharmacist manager), weekend and evening penalty rates in a seven-day trading model, and superannuation at 12% from 1 July 2025. Underpayment claims in retail pharmacy are common and expensive — annualised salary arrangements need regular reconciliation against the award. A pharmacy with $1.3 million of wages is also over the NSW payroll tax threshold ($1.2 million for 2025–26, at 5.45%), and groups of commonly owned pharmacies are aggregated for the threshold.

Buying or selling a pharmacy — the most regulated deal in small business

Price is built on adjusted EBITDA and scripts. Buyers analyse daily script volumes, government revenue percentage, and normalised earnings — with the owner-pharmacist’s wages restated at market rates.
Approval numbers and location rules. The PBS approval attaching to the premises is the asset; Commonwealth location rules constrain new approvals and relocations, which is why established approvals carry the goodwill value they do.
Eligibility of the buyer. Only registered pharmacists (within the five-pharmacy cap) can buy in NSW — shrinking the buyer pool and making vendor finance and staged equity sales to employed pharmacists a common exit path that requires careful tax structuring.
Stock at valuation. The settlement-day stocktake routinely moves the price by $50,000 or more; agreeing the methodology in the contract avoids the classic settlement dispute.
Small business CGT concessions. A pharmacist selling a long-held pharmacy may, where eligible, dramatically reduce or eliminate CGT using the 15-year exemption or the 50% active asset reduction plus retirement exemption — but eligibility depends on tests measured at and before the sale, so the planning belongs years earlier.

Worked example — the Kingsgrove pharmacy’s margin rebuild

A Kingsgrove pharmacy turning over $3.8 million came to us frustrated: turnover had grown, but profit had fallen for two years. The accounts showed a blended gross margin of 28.4% and nothing else useful. Rebuilding the reporting by department told the real story: dispensary GP% had compressed about 1.4 points since 60-day dispensing scaled up (roughly $33,000 a year on its dispensary turnover), front-of-shop stock had blown out to $210,000 with a stock turn of 2.1, and the pharmacy was missing its wholesaler settlement discount roughly one month in three — another $18,000 a year of leaked margin.

The twelve-month plan: a stock reduction program took $70,000 out of front-of-shop inventory and released the cash to pay wholesalers inside discount terms every month; the freed capacity funded a vaccination and medication-review push that added approximately $46,000 of service revenue at strong margins; and the ACSS uplift from 1 July 2025 was tracked as its own revenue line so the owner could finally see the 60-day effect in dollars. Net profit improved by approximately $74,000 on broadly flat turnover — all of it from measurement and discipline, none of it from selling more.

A Trinity insight from 22 years in practice

Pharmacy owners are scientists by training, and the irony we see after 22 years is that many run their dispensaries with clinical precision and their businesses on a blended gross margin percentage and a gut feel. The pharmacies that prosper through every PBS reform — and there has been one every few years since we opened in 2003 — are the ones that measure at the department level, reconcile their PBS statements, and treat stock as cash on a shelf. Regulation sets your prices; measurement protects your margin. Only one of those is in your control.

What this means for you

If your accounts show one blended gross margin: ask for department-level reporting — it is the single most valuable change a pharmacy can make to its numbers.
If you cannot say what 60-day dispensing costs you per quarter: your chart of accounts needs restructuring to track the ACSS line and dispensary GP% separately.
If front-of-shop stock turns fewer than 3 times a year: you are funding shelf decoration with money your wholesaler discount needs.
If you are on annualised salaries: reconcile against the Pharmacy Industry Award at least annually — underpayment exposure compounds quietly.
If you are planning succession or sale: start the CGT concession and buyer-eligibility planning now — the restricted NSW buyer pool makes pharmacy exits slower and more structured than other businesses.
If anyone has proposed a structure giving a non-pharmacist a share of pharmacy profits: have it checked against the NSW financial interest rules before signing anything.

How Trinity can help

Trinity Accounting Practice provides pharmacy-focused accounting for Sydney owners: department-level margin reporting on Xero, PBS statement reconciliation, stock and cash flow disciplines that capture wholesaler terms, award and payroll tax compliance, partnership and ownership structuring within the NSW rules, and buy-side or sell-side support including small business CGT concession planning and vendor-finance structuring for staged exits. We are five minutes from the King Georges Road pharmacy strip and have served the St George area’s small businesses since 2003.

Book a pharmacy accounting chat with the Trinity team →

General advice only. This article contains general information current as at June 2026 and does not constitute tax, financial or legal advice. It does not take into account your personal circumstances, objectives or needs. Before acting on any information in this article, you should consider its appropriateness to your situation and seek professional advice from Trinity Accounting Practice or another qualified adviser. Liability limited by a scheme approved under Professional Standards Legislation.